Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation
- PMID: 1739623
- PMCID: PMC1977731
- DOI: 10.1038/bjc.1992.47
Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation
Abstract
A fusion protein consisting of the humanised Fab fragment of the anti CEA MAb BW 431 and the human beta-glucuronidase was expressed in BHK cells. Functional testing revealed that the specificity and avidity of the humanised V region was similar to the original murine MAb BW 431. Furthermore, the enzymatic activity, pH sensitivity and stability of the human beta-glucuronidase in the fusion protein was comparable to the activity of recombinant human beta-glucuronidase. Using anti-idiotype affinity chromatography, two molecules of a molecular weight of 125 kDa or 250 kDa could be visualized under nonreducing conditions in SDS-PAGE. Reducing conditions revealed a 25 kDa light and 100 kDa heavy chain. Due to its suitable biological characteristics this fusion protein might be an appropriate molecule allowing a site specific antibody directed enzyme prodrug therapy (ADEPT) in vivo.
Similar articles
-
Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.Blood. 1998 Jul 1;92(1):184-90. Blood. 1998. PMID: 9639515
-
Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).Cancer Biother Radiopharm. 2003 Jun;18(3):339-53. doi: 10.1089/108497803322285099. Cancer Biother Radiopharm. 2003. PMID: 12954121
-
In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein.Immunotechnology. 1996 Feb;2(1):47-57. doi: 10.1016/1380-2933(96)00033-4. Immunotechnology. 1996. PMID: 9373327
-
Tumor-selective prodrug activation by fusion protein-mediated catalysis.Cancer Res. 1994 Apr 15;54(8):2151-9. Cancer Res. 1994. PMID: 8174122
-
Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Expert Opin Biol Ther. 2017 Jan;17(1):1-13. doi: 10.1080/14712598.2017.1247802. Epub 2016 Oct 24. Expert Opin Biol Ther. 2017. PMID: 27737561 Review.
Cited by
-
Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.Cell Biophys. 1994;24-25:127-33. doi: 10.1007/BF02789223. Cell Biophys. 1994. PMID: 7736516
-
Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-beta-glucuronidase conjugate in the specific treatment of cancer.Cell Biophys. 1994;24-25:185-92. doi: 10.1007/BF02789229. Cell Biophys. 1994. PMID: 7736523
-
Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial.Cell Biophys. 1992 Aug-Dec;21(1-3):109-20. doi: 10.1007/BF02789482. Cell Biophys. 1992. PMID: 1285323 Clinical Trial.
-
Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells.Biochem J. 1994 Aug 1;301 ( Pt 3)(Pt 3):821-8. doi: 10.1042/bj3010821. Biochem J. 1994. PMID: 8053907 Free PMC article.
-
The role of beta-glucuronidase in drug disposition and drug targeting in humans.Clin Pharmacokinet. 1997 Jul;33(1):18-31. doi: 10.2165/00003088-199733010-00003. Clin Pharmacokinet. 1997. PMID: 9250421 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials